Vistagen Therapeutics, Inc. financial data

Symbol
VTGN on Nasdaq
Industry
Pharmaceutical Preparations
Location
343 Allerton Avenue, South San Francisco, CA
State of incorporation
Nevada
Fiscal year end
March 31
Former names
Excaliber Enterprises, Ltd. (to 6/8/2011)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.16K % +345%
Debt-to-equity 8.58 % -84.1%
Return On Equity -35.1 % +86.9%
Return On Assets -32.4 % +81.4%
Operating Margin 26.1K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27M shares +243%
Entity Public Float 62.7M USD +101%
Common Stock, Value, Issued 27K USD +242%
Weighted Average Number of Shares Outstanding, Basic 30.6M shares +317%
Weighted Average Number of Shares Outstanding, Diluted 30.6M shares +317%

Income Statement

Label TTM Value / Value Unit Change %
Revenues -227K USD -120%
Research and Development Expense 23.5M USD -29.5%
General and Administrative Expense 15.7M USD +21.8%
Operating Income (Loss) -38.2M USD +17.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -33.2M USD +28.4%
Income Tax Expense (Benefit) 1K USD -75%
Net Income (Loss) Attributable to Parent -33.2M USD +28.4%
Earnings Per Share, Basic -0.93 USD/shares +85.9%
Earnings Per Share, Diluted -0.35 USD/shares +62.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 103M USD +970%
Cash, Cash Equivalents, and Short-term Investments 108M USD
Assets, Current 111M USD +857%
Property, Plant and Equipment, Net 489K USD +2.77%
Operating Lease, Right-of-Use Asset 1.7M USD -20.9%
Other Assets, Noncurrent 518K USD
Assets 114M USD +655%
Accounts Payable, Current 1.21M USD -25.5%
Employee-related Liabilities, Current 17.3K USD -92.8%
Accrued Liabilities, Current 2.16M USD +410%
Contract with Customer, Liability, Current 2.3M USD +221%
Liabilities, Current 6.24M USD +54%
Contract with Customer, Liability, Noncurrent 1.09M USD -49.2%
Operating Lease, Liability, Noncurrent 1.42M USD -28.5%
Liabilities 8.75M USD +6.86%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2K USD
Retained Earnings (Accumulated Deficit) -367M USD -9.95%
Stockholders' Equity Attributable to Parent 105M USD +1430%
Liabilities and Equity 114M USD +655%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.9M USD -37.7%
Net Cash Provided by (Used in) Financing Activities 88K USD -89.9%
Net Cash Provided by (Used in) Investing Activities -5.47M USD
Common Stock, Shares Authorized 325M shares 0%
Common Stock, Shares, Issued 27.1M shares +243%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16.2M USD -132%
Deferred Tax Assets, Valuation Allowance 60.5M USD +2.14%
Deferred Tax Assets, Gross 60.5M USD +2.17%
Operating Lease, Liability 2.12M USD -18.6%
Payments to Acquire Property, Plant, and Equipment 175K USD +16.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -10.7M USD -55.5%
Lessee, Operating Lease, Liability, to be Paid 2.45M USD -22%
Property, Plant and Equipment, Gross 1.69M USD -0.65%
Operating Lease, Liability, Current 567K USD +13.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 732K USD +3.07%
Lessee, Operating Lease, Liability, to be Paid, Year One 710K USD +2.97%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 329K USD -38.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 753K USD +2.94%
Deferred Tax Assets, Operating Loss Carryforwards 46.5M USD +6.56%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.93M USD +284%
Lessee, Operating Lease, Liability, to be Paid, Year Four 254K USD -66.3%
Operating Lease, Payments 223K USD +8.83%
Additional Paid in Capital 476M USD +38.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 34K USD +6.25%
Deferred Tax Assets, Net of Valuation Allowance 20K USD +300%
Share-based Payment Arrangement, Expense 2.77M USD -5.97%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%